2018 PhD Molecular Pathology Newcastle University , Faculty of Medicine
2007 M.Sc. Histopathology Al-Nahrain University, College of Medicine
2000 M.B.Ch.B (Bachelor in Medicine and General Surgery) Al-Nahrain University, College of Medicine
السيرة
Biography
التدريس
Teaching
Presenting pathology lectures to 3rd grade medical students.
Presenting and directing pathology practical lab sessions to 3rd grade medical students and 5th stage surgical pathology
الدراسات العليا
Post graduate
Molecular pathology lectures and labs for postgraduate PhD students
الاهتمامات البحثية
Research Interests
Exploring the effects of targeted anticancer compounds on gene transcription and protein signalling pathways in multiple cancer cell line models using molecular pathology techniques including ShRNA & CRSPR gene editing.
Exploring the effect of ALIOs diet on NAFLD and HCC development in murine animal model.
Exploring the effect of MDM2 and PPM1D/WIP1 inhibitors on liver cancer.
النشاطات
Scientific Activities
2022 2nd RESET ageing Conference Newcastle Attendance and preconference school Attended the Training School - Single cell techniques in senescence and ageing
2020 Anbar International Medical Conference, AIMCO-2020 Anbar attendance
2018 EASL Congress Paris Talk What drives development of HCC in non-cirrhotic NAFLD?
2018 EASL - HCC Summit Geneva e-poster Combined targeting of the PPM1D/WIP1 and MDM2 negative feedback suppressors of p53 in TP53 wild-type human liver cancer cells
2017 AASLD-American Association for the Study of Liver Disease. Washington DC poster MDM2 inhibition for non-genotoxic activation of TP53 – a novel strategy for the treatment of hepatocellular carcinoma (HCC).
2017 AASLD-American association for the study of liver disease. Washington DC poster Lipogranuloma, neutrophils and progression of NAFLD to NASH and HCC.
2017 AACR annual meeting Washington DC poster Inhibition of WIP1/PPM1D phosphatase by GSK2830371 potentiates the growth inhibitory and cytotoxic activity of MDM2 antagonist (nutlin-3, RG7388 and HDM201) in cutaneous melanoma cells.
2016 San Antonio Breast Cancer Symposium Texas poster Cytotoxic potential of the RG7388-p53 binding antagonist and the GSK2830371 WIP1 inhibitor on MX-1 and MCF-7 human breast cancer cells.
2016 EACR 24th Biennial congress Manchester poster MDM2 antagonists – a therapeutic approach for patients with hepatocellular carcinoma?
2015 ILCA- International Liver Cancer association 9th annual conference Paris e-poster DNA Damage Caused By Dietary Induced Steatohepatitis Correlates With Hepatocellular Carcinoma Development and Progression.
2015 BASL-British Association for the Study of the Liver annual meeting Newcastle attendance
المنشورات
Publications
2023 Immunohistochemical expression of CD117 in borderline, low- and high-grade ovarian surface epithelial tumours: A clinicopathological study Malays J Pathol 2023; 45(2) : 229 – 236
2021 Key features of the environment promoting liver cancer in the absence of cirrhosis Scientific Reports; 11, Article number: 16727 (2021)
2018 Targeting negative regulation of p53 by MDM2 and WIP1 as a therapeutic strategy in cutaneous melanoma. British Journal of Cancer; 118, 495-508
2012 PCNA expression in Cag A strain H. Pylori gastritis: immunohistochemical & in situ hybridization study. Iraqi Journal of Medical Sciences., Vol. 10 Issue 2, p160-166. 7p.
2006 Immunohistochemical expression of (CD15, CD20) to reclassify the Lymphocyte Predominance Hodgkin’s Lymphoma. M.Sc. thesis